Bibliography
- CLARK I, PARKER A: Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin. The]: Targets (2003) 7(1):19–34.
- COUSSENS L, FINGLETON B, MATRISIAN L: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387–2392.
- •Evaluation of MMP inhibitors in cancer biology and clinical trials.
- HENROTIN Y, SANCHEZ C, REGINSTER J: The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin. The]: Patents (2002) 12(1):29–43.
- WHITTAKER M, FLOYD C, BROWN P, GEARING A: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev (1999) 99(9):2735–2776.
- •Most comprehensive review of MMP inhibitor designs.
- BROWN P: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Invest. Drugs (2002) 9(9):2167–2177.
- PALLADINO M, BAHJAT F, THE ODORAKIS E, MOLDAWER L: Anti-TNF-a therapies: the next generation. Nat. Rev Drug Discov. (2003) 2(9):736–746.
- SFIKAKIS P, KOLLIAS G: Tumor necrosisfactor biology in experimental and clinical arthritis. Curr. Opin. Rheum. (2003) 15:380–386.
- KUMAR S, BOEHM J, LEE J: p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nature Rev Drug Discov. (2003) 2(9):717–726.
- PARGELIS C, REGAN J: Inhibitiors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curc Opin. Invest. Drugs (2003) 4(5):566–571.
- SKOTNICKI J, LEVIN J: TNF-a-converting enzyme (TACE) as a therapeutic target. In: Annual Reports M Medicinal Chemistry (Volume 38). Doherty AM (Ed.), Elsevier Academic Press, San Diego, CA, USA (2003):153–162.
- •Latest review of TACE.
- DUAN J, LU Z, XUE C et al: Discovery of N-hydroxy 2 (2 oxo 3 pyrrolidinA acetamides as potent and selective inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. (2003) 13:2035-2040. See also references cited within this paper.
- CLOSE D: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. (2001) 603662-11i67.
- LEVIN J, CHEN J, CHEUNG K et al.: Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg. Med. Chem. Lett. (2003) 13(16):2798–2803. An example of a number of papers in this area.
- CONWAY J, ANDREWS R, BEAUDET B et al.: Inhibition of tumor necrosis factor-a (TNF-a) production and arthritis in rat by GW-3333, a dual inhibitor of TNF-a-converting enzyme and matrix metalloproteinases. Pharmacol Exp. The]: (2001) 298:900–908.
- LETAVIC M, BARBERIA J, CARTY T et al.: Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-a-converting enzyme inhibitors. Bioorg. Med. Chem. Lett. (2003) 13(19):3243–3246. An example of a number of papers in this area.